中國能源建設AH齊漲 去年新籤合同額累計8726.1億元 同比增長51%
格隆匯1月18日丨中國能源建設(03996.HK)漲3.23%,報1.28港元;中國能建亦漲3.35%,報2.78元。中國能源建設昨晚發佈公吿,2021年度,公司新籤合同額本年累計8,726.1億元人民幣,同比增長51%。浙商證券隨後發佈研報稱,公司新籤合同額兩年複合增速30%,其中新能源及綜合智慧能源業務訂單同比高增53%。新簽訂單超預期。公司作為能源電力建設行業國家隊,“十四五”發展規劃明確提出“五年再造一個高質量發展的新能建”,獲取新能源基建項目訂單、節奏如期兑現,未來業績成長高彈性可期!

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.